Integrative Research Laboratories Sweden

IRLAB Therapeutics is a Swedish clinical-stage biotechnology company focused on developing novel treatments for central nervous system (CNS) disorders, with a primary emphasis on Parkinson's disease. The company utilizes its proprietary Integrative Screening Process (ISP) platform to discover compounds that target complex brain functions by analyzing large-scale patterns of drug-induced gene expression and behavior. Its lead candidates include mesdopetam, which has completed Phase 2b trials for levodopa-induced dyskinesia, and pirepemat, currently in Phase 2b for impaired balance and falls. IRLAB is publicly traded on the Nasdaq Stockholm and maintains a robust pipeline of small molecule candidates designed to address significant unmet needs in neurology. The company's unique approach combines systems biology with advanced machine learning to identify drug candidates with high clinical potential.